Cipla Ltd.

BSE: CIPLA500087ISIN INE059A01026

Healthcare
Pharmaceuticals
BSE 100

BSE listing

Share price

₹1,371.45-0.80 (-0.06%)

as of 18 Sep 2026

52W high: ₹1,672.20
52W low: ₹1,165.55
Off 52W high: -17.99%
1M return: -3.15%
3M return: +1.30%
6M return: +9.20%
1Y return: -13.11%
20D avg volume: 42,359
50 DMA: ₹1,423.65
200 DMA: ₹1,387.38

Key ratios Consolidated

Market cap: ₹1,10,794 Cr
Current price: ₹1,371.45
52W high / low: ₹1,672.20 / ₹1,165.55
Face value: ₹2.00
P/E: 35.19
P/B: —
EPS (TTM): ₹41.54
Book value / share: —
ROE: —
ROCE: 14.90%
Operating margin: —
Net margin: —
Debt / equity: 0.01
Net debt: ₹-760.25 Cr
Interest cover: 97.04
Dividend yield: 0.95%
Dividend / share (TTM): ₹13.00
Payout: 31.30%
Cash conversion cycle: 116.4 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	7,119	6,541	7,074	7,589	6,957	6,730	7,073	7,051	6,694	6,163	6,604	6,678
	210.90	148.16	206.34	268.95	258.56	289.46	221.61	190.61	160.19	249.33	184.63	176.32
	6,248	5,982	6,112	6,005	5,446	5,515	5,378	5,453	5,243	5,153	5,120	5,260
	1,357	1,382	1,462	1,528	1,469	1,398	1,297	1,474	1,241	1,253	1,196	1,473
	1,252	1,285	1,249	892.98	1,025	1,024	913.23	814.59	1,100	738.96	927.21	890.19
	1,497	1,414	1,325	1,315	1,312	1,233	1,198	1,208	1,194	1,084	1,068	1,091
	17.03	13.13	14.03	13.18	14.05	14.02	14.64	15.40	17.95	17.59	30.10	25.80
	304.24	382.92	278.35	296.99	252.72	308.73	279.80	271.74	246.68	288.34	233.43	290.04
	1,762	1,923	1,862	1,882	1,696	1,770	1,622	1,675	1,591	1,713	1,569	1,540
	1,082	707.06	1,169	1,854	1,770	1,504	1,916	1,789	1,611	1,259	1,669	1,594
	0.00	0.00	-275.91	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-194.82	0.00
	1,082	707.06	893.11	1,854	1,770	1,504	1,916	1,789	1,611	1,259	1,474	1,594
	294.83	156.95	218.55	500.46	477.88	279.28	332.37	483.04	435.07	324.86	405.30	438.41
	785.55	542.51	674.25	1,353	1,292	1,214	1,575	1,305	1,175	931.87	1,068	1,155
	9.77	6.87	8.37	16.73	16.07	15.13	19.45	16.13	14.58	11.63	13.08	14.01
Key metrics
	1,403	1,103	1,185	2,164	2,037	1,827	2,211	2,076	1,876	1,565	1,737	1,910
	19.70%	16.90%	16.80%	28.50%	29.30%	27.10%	31.30%	29.40%	28.00%	25.40%	26.30%	28.60%
	11.00%	8.30%	9.50%	17.80%	18.60%	18.00%	22.30%	18.50%	17.60%	15.10%	16.20%	17.30%
	—	2.00%	—	5.50%	—	4.80%	—	—	—	—	—	—
	2.30%	-2.80%	0.00%	7.60%	3.90%	9.20%	7.10%	5.60%	—	—	—	—
	-39.20%	-55.30%	-57.20%	3.70%	9.90%	30.30%	47.40%	13.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	28,324	28,163	27,548	25,774	22,753	21,763	19,160	17,132	16,362	15,219
	834.35	882.01	861.87	746.57	475.45	280.91	265.99	344.20	476.57	357.65
	24,347	23,545	21,589	20,624	19,008	18,369	16,136	15,298	14,760	13,830
	5,729	5,842	5,410	5,221	5,520	5,533	4,886	4,377	4,285	4,497
	4,678	4,451	3,851	3,536	2,829	3,687	2,658	1,859	1,452	1,174
	5,551	5,366	4,833	4,310	3,830	3,530	3,252	3,027	2,857	2,690
	57.37	54.39	62.01	89.88	109.54	106.35	160.70	197.36	168.43	114.23
	1,262	1,211	1,107	1,051	1,172	1,052	1,068	1,175	1,326	—
	7,430	7,364	6,658	6,353	5,644	5,185	4,303	4,908	4,624	4,264
	4,812	5,500	6,821	5,897	4,221	3,675	3,290	2,178	2,079	1,747
	-275.91	-275.91	0.00	-194.82	-182.42	-182.12	0.00	0.00	0.00	-77.52
	4,536	5,224	6,821	5,702	4,038	3,493	3,290	2,178	2,079	1,669
	1,171	1,354	1,530	1,547	1,203	933.80	888.76	631.20	569.53	250.11
	3,356	3,862	5,269	4,154	2,833	2,547	2,389	1,500	1,492	1,419
	41.74	48.03	65.29	51.05	34.72	31.20	29.82	19.19	18.97	—
Key metrics
	5,856	6,489	7,990	6,843	5,320	4,652	4,518	3,550	3,574	1,784
	20.67%	23.00%	29.00%	26.50%	23.40%	21.40%	23.60%	20.70%	21.80%	11.70%
	11.85%	13.70%	19.10%	16.10%	12.50%	11.70%	12.50%	8.80%	9.10%	9.30%
	—	14.90%	21.60%	—	—	—	—	—	—	—
	—	2.20%	6.90%	13.30%	4.50%	13.60%	11.80%	4.70%	7.50%	—
	—	-26.70%	26.90%	46.60%	11.20%	6.60%	59.30%	0.50%	5.10%	—
	—	2,341	3,843	—	—	—	—	—	—	—
	—	1.02	0.95	—	—	—	—	—	—	—
	—	0.01	0.00	—	—	—	—	—	—	—
	—	-760.25	-496.59	—	—	—	—	—	—	—
	—	116.4	110.2	—	—	—	—	—	—	—
Balance sheet
	—	42,496	37,387	—	—	—	—	—	—	—
	—	24,146	23,249	—	—	—	—	—	—	—
	—	1,018	588.69	—	—	—	—	—	—	—
	—	5,620	5,506	—	—	—	—	—	—	—
	—	6,597	5,642	—	—	—	—	—	—	—
	—	1,459	1,055	—	—	—	—	—	—	—
	—	6,040	5,262	—	—	—	—	—	—	—
	—	3,230	2,837	—	—	—	—	—	—	—
	—	7,014	5,484	—	—	—	—	—	—	—
	—	257.97	92.10	—	—	—	—	—	—	—
	—	140.50	80.12	—	—	—	—	—	—	—
	—	117.47	11.98	—	—	—	—	—	—	—
	—	34,520	31,289	—	—	—	—	—	—	—
Cash flow
	—	3,940	5,005	—	—	—	—	—	—	—
	—	-2,326	-3,691	—	—	—	—	—	—	—
	—	-1,234	-1,293	—	—	—	—	—	—	—
	—	1,599	1,162	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	5,078	4,210	4,498	5,226	5,046	4,798	4,971	4,775	4,501	4,037	4,381	4,665
	242.75	180.22	416.70	254.66	271.07	293.37	188.69	289.14	213.52	538.61	168.98	205.09
	4,167	3,868	3,934	3,847	3,573	3,630	3,455	3,486	3,284	3,351	3,170	3,473
	1,039	965.58	1,004	1,005	1,018	923.60	940.73	974.92	803.59	517.24	677.74	1,001
	651.15	763.51	746.64	530.39	547.43	464.76	475.64	544.27	572.08	467.43	537.32	654.61
	914.96	869.24	822.93	840.01	818.30	784.93	761.45	744.58	763.91	662.15	648.22	694.71
	5.68	6.74	4.03	2.65	5.88	3.49	3.55	3.00	5.07	5.45	9.06	7.80
	169.39	218.11	153.33	141.30	145.69	147.70	142.62	145.71	137.86	136.81	135.02	179.81
	1,366	1,397	1,327	1,304	1,182	1,313	1,176	1,174	1,080	1,385	1,012	1,074
	1,154	522.48	980.54	1,633	1,744	1,461	1,704	1,578	1,430	1,224	1,381	1,397
	0.00	0.00	-244.37	0.00	0.00	294.66	—	—	—	—	—	—
	1,154	522.48	736.17	1,633	1,744	1,756	1,704	1,578	1,430	1,224	1,381	1,397
	291.46	137.84	119.29	422.81	440.82	270.15	266.20	400.31	374.51	242.21	363.00	366.91
	862.16	384.64	616.88	1,211	1,303	1,485	1,438	1,178	1,056	1,038	1,114	1,030
	10.67	4.76	7.64	14.99	16.13	18.39	17.81	14.59	13.08	12.16	12.61	12.76
Key metrics
	1,329	747.33	893.53	1,777	1,896	1,907	1,851	1,727	1,573	1,366	1,525	1,584
	26.20%	17.80%	19.90%	34.00%	37.60%	39.70%	37.20%	36.20%	35.00%	33.90%	34.80%	34.00%
	17.00%	9.10%	13.70%	23.20%	25.80%	31.00%	28.90%	24.70%	23.50%	25.70%	25.40%	22.10%
	—	1.50%	—	4.90%	—	5.40%	—	—	—	—	—	—
	0.60%	-12.30%	-9.50%	9.40%	12.10%	18.90%	13.50%	2.40%	—	—	—	—
	-33.80%	-74.10%	-57.10%	2.70%	23.40%	43.00%	29.10%	14.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	19,011	18,980	19,045	16,574	15,791	13,092	13,901	12,659	12,374	11,445
	1,094	1,123	984.72	1,071	456.79	666.70	230.28	892.85	577.52	334.88
	15,816	15,222	13,855	12,698	12,621	10,212	10,780	10,588	10,459	9,791
	4,013	3,992	3,643	2,617	3,503	2,768	3,262	2,999	3,112	3,303
	2,692	2,588	2,057	2,360	1,993	2,851	1,848	1,363	1,259	1,064
	3,447	3,350	3,055	2,644	2,377	1,729	2,039	1,911	1,840	1,786
	19.10	19.30	15.11	20.25	27.02	26.93	45.07	36.05	16.97	11.90
	682.13	658.43	573.89	587.59	595.91	460.01	556.11	599.78	569.72	529.61
	5,394	5,210	4,742	4,364	3,919	2,906	3,040	3,722	3,524	3,308
	4,290	4,880	6,174	4,947	3,626	3,546	3,351	2,964	2,493	1,989
	-244.37	-244.37	294.66	—	-185.90	—	—	—	—	-77.52
	4,046	4,636	6,469	4,947	3,441	3,546	3,351	2,964	2,493	1,911
	971.40	1,121	1,311	1,233	971.01	856.84	882.38	646.14	604.42	442.88
	3,074	3,515	5,158	4,077	2,513	2,958	2,468	2,318	1,888	1,469
	38.06	43.52	63.87	46.01	30.61	33.34	30.61	28.76	23.45	—
Key metrics
	4,747	5,314	7,058	5,555	4,063	4,033	3,952	3,600	3,080	2,453
	24.97%	28.00%	37.10%	33.50%	25.70%	30.80%	28.40%	28.40%	24.90%	21.40%
	16.17%	18.50%	27.10%	24.60%	15.90%	22.60%	17.80%	18.30%	15.30%	12.80%
	—	13.40%	20.00%	—	—	—	—	—	—	—
	—	-0.30%	14.90%	5.00%	20.60%	-5.80%	9.80%	2.30%	8.10%	—
	—	-31.80%	26.50%	62.20%	-15.00%	19.80%	6.50%	22.80%	28.60%	—
	—	2,051	2,730	—	—	—	—	—	—	—
	—	0.81	0.64	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-238.20	-82.74	—	—	—	—	—	—	—
	—	109.4	107.0	—	—	—	—	—	—	—
Balance sheet
	—	38,493	35,566	—	—	—	—	—	—	—
	—	17,912	18,369	—	—	—	—	—	—	—
	—	248.80	82.74	—	—	—	—	—	—	—
	—	3,397	3,860	—	—	—	—	—	—	—
	—	4,354	3,607	—	—	—	—	—	—	—
	—	1,041	675.11	—	—	—	—	—	—	—
	—	3,782	3,508	—	—	—	—	—	—	—
	—	2,062	1,884	—	—	—	—	—	—	—
	—	3,872	3,183	—	—	—	—	—	—	—
	—	10.60	0.00	—	—	—	—	—	—	—
	—	10.60	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	34,201	32,099	—	—	—	—	—	—	—
Cash flow
	—	2,832	3,301	—	—	—	—	—	—	—
	—	-1,344	-2,309	—	—	—	—	—	—	—
	—	-1,322	-1,074	—	—	—	—	—	—	—
	—	780.69	571.06	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +6.32%
Sales CAGR 5Y: +6.43%
Sales CAGR 10Y: —
Profit CAGR 3Y: +11.83%
Profit CAGR 5Y: +7.33%
Profit CAGR 10Y: —
Sales YoY (TTM): -2.95%
Profit YoY (TTM): -43.12%

Consolidated

Sales CAGR 3Y: +7.37%
Sales CAGR 5Y: +8.01%
Sales CAGR 10Y: —
Profit CAGR 3Y: +10.88%
Profit CAGR 5Y: +10.09%
Profit CAGR 10Y: —
Sales YoY (TTM): +1.85%
Profit YoY (TTM): -37.69%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 29.22%

Quarter	June 2026	March 2026
Promoter %	29.22%	29.22%

Holder	Type	Holding	Previous	Change
Yusuf Khwaja Hamied	Promoter	18.69%	—	—
LICI ULIP-GROWTH FUND	Public	9.75%	—	—
SOPHIE AHMED	Promoter Group	5.71%	5.71%	0.00%
HDFC TRUSTEE COMPANY LIMITED-HDFC FLEXI CAP FUND	Public	4.48%	—	—
M K HAMIED	Promoter	3.46%	3.46%	0.00%
SBI NIFTY 50 EQUAL WEIGHT INDEX FUND	Public	3.24%	—	—
ICICI PRUDENTIAL EQUITY SAVINGS FUND	Public	2.36%	—	—
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA ARB	Public	1.96%	1.69%	+0.27%
DSP NIFTY 50 INDEX FUND	Public	1.90%	—	—
PARAG PARIKH ARBITRAGE FUND	Public	1.87%	—	—
NPS TRUST A/C - LIC PENSION FUND - UPS - CG SCHEM	Public	1.71%	1.69%	+0.02%
Kamil Hamied	Promoter Group	1.36%	1.36%	0.00%
GOVERNMENT PENSION FUND GLOBAL	Public	1.30%	1.37%	-0.07%
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	Public	1.04%	1.02%	+0.02%
Hamsons Laboratories LLP	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Please find enclosed disclosure on ESG Rating.18 Sep 2026 · Company Update / General
Please find enclosed press release titled ''Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US''3 Sep 2026 · Company Update / Press Release / Media Release
Please find enclosed disclosure3 Sep 2026 · Company Update / General
Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares2 Sep 2026 · Company Update / Newspaper Publication
Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"31 Aug 2026 · Company Update / Press Release / Media Release
Please find enclosed disclosure.28 Aug 2026 · Company Update / General
Please find enclosed disclosure.27 Aug 2026 · Company Update / Restructuring
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / ....27 Aug 2026 · Company Update / Analyst / Investor Meet
In terms of regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Admisnistrative Committee of the Company on 26th August, 2026 has allotted 5,281 fully ....26 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed disclosure25 Aug 2026 · Company Update / General
Cipla has informed the exchange about receipt of order from Hon''ble NCLT, Mumbai Bench19 Aug 2026 · Company Update / Scheme of Arrangement
Please find attached disclosure on ESG Ratings.11 Aug 2026 · Company Update / General
Please find enclosed intimation.4 Aug 2026 · Company Update / General
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015, we hereby notify that the Operations and Administrative Committee ....31 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed disclosure27 Jul 2026 · Company Update / General
Please find enclosed Earnings Call Transcript - Q1FY2727 Jul 2026 · Company Update / Earnings Call Transcript
Please find attached newspaper intimation for unaudited financial results for the quarter ended 30th June, 2026.24 Jul 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the ....23 Jul 2026 · Company Update / Analyst / Investor Meet
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed disclosure on Regulation 30(5)23 Jul 2026 · Company Update / General
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed the disclosure relating to the change in SMP.23 Jul 2026 · Company Update / Change in Management
Please find enclosed the disclosure relating to the change in CFO.23 Jul 2026 · Company Update / Change in Management
Please find enclosed outcome of Board meeting.23 Jul 2026 · Board Meeting / Outcome of Board Meeting
Please find attached press release for Q1FY27 financial results23 Jul 2026 · Company Update / Press Release / Media Release
Please find attached Investor Presentation23 Jul 2026 · Company Update / Investor Presentation
Please find attached financial results for quarter ended 30th June, 202623 Jul 2026 · Result / Financial Results
Please find enclosed disclosure on USFDA inspection at InvaGen manufacturing facility in Long Island, NY, USA18 Jul 2026 · Company Update / General
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 201813 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed disclosure on ESG Rating.12 Jul 2026 · Company Update / General
We are enclosing herewith earnings call intimation scheduled to be held on 23rd July 2026.8 Jul 2026 · Company Update / Analyst / Investor Meet
Please find enclosed transcript.4 Jul 2026 · Company Update / General
Please find enclosed transcript.3 Jul 2026 · Company Update / General
Please find attached newspaper publication regarding opening of special window of lodgement of transfer and dematerialisation of physical shares.2 Jul 2026 · Company Update / Newspaper Publication
Please find enclosed intimation25 Jun 2026 · Company Update / Appointment of Statutory Auditor/s
Please find enclosed Proceedings of AGM25 Jun 2026 · AGM/EGM / AGM
Details of voting results of the 90th Annual General Meeting of the Company and Scrutiniser''s report25 Jun 2026 · AGM/EGM / AGM

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 13.0000	5 Jun 2026	5 Jun 2026	—
Special Dividend - Rs. - 3.0000	27 Jun 2025	27 Jun 2025	—
Final Dividend - Rs. - 13.0000	27 Jun 2025	27 Jun 2025	—
Final Dividend - Rs. - 13.0000	2 Aug 2024	2 Aug 2024	—

Board meetings

23 Jul 2026 Board Meeting - Financial Results